For more than 30 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription drug costs.

What is the 340B Program? This program, administered by the Health Resources and Services Administration (HRSA), allows 340B hospitals to stretch limited federal resources to reduce the price of outpatient pharmaceuticals for patients and expand health services to the patients and communities they serve. Hospitals use 340B savings to provide, for example, free care for uninsured patients, offer free vaccines, provide services in mental health clinics, and implement medication management and community health programs. According to HRSA, enrolled hospitals and other covered entities can achieve average savings of 25% to 50% in pharmaceutical purchases.

Which organizations are eligible? Several types of hospitals are eligible to participate in the 340B program including critical access hospitals (CAHs), sole community hospitals (SCHs), rural referral centers (RRCs), public and private nonprofit disproportionate share hospitals (DSHs) that serve high numbers of low-income and indigent populations, and free-standing cancer and children’s hospitals. Several types of federal grantee organizations such as community health centers also are eligible to participate in the program.

What are some challenges to the program? Despite rigorous oversight from HRSA and the program’s proven record of expanding access to care for Americans nationwide, critics continue to push to diminish the scope of the program and the benefits it affords eligible providers and their patients.
 

340B Resources

 

Member Resources


 

Join the 340B Alliance Banner

The AHA Advocacy Alliance for the 340B program focuses on promoting the value that the 340B program provides to hospitals, patients and communities, as well as preventing attempts to scale back this program. Join the alliance for access to email communications, conference calls and special briefings. Join the Alliance.


Through email communications like alliance emails, action alerts and special messages, the 340B Alliance keeps hospitals informed of the latest news and developments on the program, as well as actions hospital leaders can take to support the program. Learn More

 

Image of medicine in pharmacy

 

Latest 340B Content

Headline
The AHA June 4 filed an amicus brief (https://www.aha.org/amicus-brief/2025-06-04-aha-files-brief-defending-tennessees-340b-contract-pharmacy-law) in the U.S. District Court for the Middle District of Tennessee in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
Amicus Brief
AHA files brief defending Tennessee’s 340B contract pharmacy law.
Headline
A U.S. district court judge for the District of Columbia May 15 ruled the Department of Health and Human Services must preapprove the use of 340B “rebate models” before they can be implemented, which the department has not yet done for any of the models pursued by the plaintiff drug companies. 
Headline
The AHA May 14 filed an amicus brief in the U.S. District Court for the District of South Dakota in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
Headline
The AHA May 9 urged the Department of Health and Human Services to deny drug companies’ requests to approve their unlawful 340B rebate models.
340B Advocacy Alliance Bulletin
340B Advocacy Alliance Bulletin for May 14, 2025.
Amicus Brief
AHA, others files brief defending South Dakota's 340B contract pharmacy law.
Letter/Comment
AHA urges Secretary U.S. Department of Health and Human Services to reject the effort by several large drug companies to undermine the 340B Drug Pricing Program by imposing a “rebate model,”
Headline
The AHA May 8 filed an amicus brief in the U.S. District Court for the District of Nebraska in defense of the state’s 340B contract pharmacy law prohibiting drug companies from denying hospitals the same 340B discounts for drugs dispensed at community pharmacies that would be provided via in-house pharmacies.
Amicus Brief
AHA, others file brief in defense of Nebraska’s 340B contract pharmacy law.